Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 8/20 | 0.41 |
| ▸ | PPARA | Q07869 | 6/20 | 0.41 |
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12096891 | 0.80 | PPARG (0.45) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL1444435 | 0.79 | PPARG (0.48) | HTR6PPARGPPARAPPARDTP53 | |
| SCHEMBL12096759 | 0.78 | PPARG (0.43) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL12096625 | 0.77 | PPARG (0.42) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL12096871 | 0.77 | ACLY (0.39) | HTR6PPARGPPARAACLYRECQL | |
| SCHEMBL12096677 | 0.77 | PPARG (0.47) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL12096853 | 0.76 | RECQL (0.43) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL12096942 | 0.75 | PPARG (0.44) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL12096659 | 0.74 | PPARG (0.45) | PPARGPPARAPPARDTP53MAPT | |
| SCHEMBL12096606 | 0.74 | PPARG (0.45) | PPARGPPARAPPARDTP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
| EP-2475642-A1 | USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE | Laboratoires Fournier S.A. (FR) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011030068-A1 | USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE | LABORATOIRES FOURNIER SA (FR) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | HTR6 129/4885PPARG 423/4885PPARA 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.